{"id":"NCT01659853","sponsor":"Galderma R&D","briefTitle":"Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","officialTitle":"A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2012-08-08","resultsPosted":"2014-07-10","lastUpdate":"2022-08-25"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Erythema","Rosacea"],"interventions":[{"type":"DRUG","name":"CD07805/47 gel 0.5%/CD07805/47 Vehicle","otherNames":["brimonidine tartrate gel 0.5%","brimonidine tartrate gel vehicle"]},{"type":"DRUG","name":"azelaic acid gel 15%","otherNames":["FinaceaÂ® gel 15%"]}],"arms":[{"label":"Overall Study","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily versus azelaic acid gel 15% applied topically twice daily in subjects with moderate to severe facial erythema of rosacea.","primaryOutcome":{"measure":"Composite Success","timeFrame":"Hour 6 on Day 15","effectByArm":[{"arm":"CD07805/47 Gel 0.5% and Vehicle","deltaMin":14.3,"sd":null},{"arm":"Azelaic Acid Gel 15%","deltaMin":5.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":70},"commonTop":["Erythema","Pruritus","Medication residue","Skin burning sensation","Pain of skin"]}}